Opus Genetics (IRD) announced that the U.S. FDA has accepted for review the supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics Closes $25 Million Series B Financing
- Opus Genetics prices 7.37M Preferred Stock at $3.39 in private placement
- Opus Genetics initiated with an Outperform at LifeSci Capital
- Opus Genetics: Favorable Risk‑Reward in OPGx-BEST1 Gene Therapy Underpins Buy Rating and $6 Price Target
- Opus Genetics: Validated AAV Platform and High-Value IRD Pipeline Underpin Buy Rating and Attractive Risk‑Reward